10 October 2024 Machine learning-enabled drug discovery and development company insitro has announced the execution of three strategic agreements with Eli Lilly.
Danish dermatology specialist Leo Pharma has revealed plans to cut 200 jobs, marking the company’s fourth workforce reduction since 2022. 11 October 2024
Booster Therapeutics, a biotechnology company pioneering a new class of proteasome activator medicines to treat neurodegenerative and other diseases, has launched with the support of a $15 million financing. 11 October 2024
German cancer specialist Immatics has announced the pricing of its $150 million public offering, with Jefferies, BofA Securities, and Leerink acting as joint book runners. 11 October 2024
The UK's Medicines and Healthcare products Regulatory Agency (MHRA) has approved Pfizer and BioNTech's latest COVID-19 vaccine, Comirnaty (KP.2). 11 October 2024
In what Astella Pharma calls “a landmark decision for advanced bladder cancer patients,” the Japanese drugmaker gained approval in the UK for its treatment regimen. 10 October 2024
Nanoscope Therapeutics says that, following a productive FDA meeting with the US Food and Drug Administration (FDA) for its clinical program evaluating MCO-010 for the treatment of retinitis pigmentosa (RP), the company will commence with submission of a Biologics License Application (BLA) in the first quarter of 2025. 10 October 2024
US healthcare giant Johnson & Johnson’s Tecvayli (teclistamab) has been recommended by the National Institute for Health and Care Excellence (NICE) as a first-line option to treat myeloma in England and Wales. 10 October 2024
China’s Quantum Pharmaceuticals has announced a significant licensing agreement between its biologics-focused subsidiary, Ailux Biologics, and Johnson & Johnson. 10 October 2024
USA-based Kezar Life Sciences announced this week that it was pausing its Phase IIb PALIZADE trial evaluating zetomipzomib in lupus nephritis (LN) following the deaths of four patients. 10 October 2024
Advances in gene editing, such as the FDA approval of Vertex Pharmaceuticals’ Casgevy (exagamglogene autotemcel) in December 2023 for the treatment of beta thalassemia and sickle cell disease, have fueled significant interest in innovative epigenetic drugs. 10 October 2024
Gene therapy start-up GEMMA Biotherapeutics (GEMMABio) has announced a significant partnership with Brazil's Fiocruz, a key supplier for the Brazilian Ministry of Health. 10 October 2024
California’s Arda Therapeutics, a biotech focused on targeted cell depletion therapies for chronic diseases, has announced the successful completion of a $43 million Series A financing round. 9 October 2024
Purespring Therapeutics, a gene therapy company focused on transforming the treatment of kidney diseases, has raised £80 million ($105 million) in a Series B financing. 9 October 2024
Australia’s biggest biotech, CSL Limited, has announced a net profit after tax of $1.73 billion for the year ending June 30, an impressive 29% rise on the previous 12 months. 15 August 2018
UK biopharma firm PureTech Health has announced the appointment of Dr Steven Paul, as chief executive of its affiliate, Karuna Pharmaceuticals. 15 August 2018
Shares in SalvaRx Group soared as much as 40.65 pence to 85.25 pence on Tuesday after the company said it has entered into a sale agreement for the disposal of its 94.2% stake in SalvaRx Limited to Canada-based Portage Biotech. 15 August 2018
The cost regulator for England and Wales has not recommending paying for Biogen’s Spinraza (nusinersen) on the National Health Service (NHS) in draft guidance published on Tuesday. 15 August 2018
USA-based Mustang Bio has entered into a partnership and exclusive license deal with St Jude Children’s Research Hospital for the development of a first-in-class ex vivo lentiviral gene therapy for children with X-linked severe combined immunodeficiency (X-SCID), or bubble boy disease. 15 August 2018
A trial failure for the UK-based biopharmaceutical firm Realm Therapeutics (LSE: RLM) has led to its share price dropping to less than half of the level that it started the week at. 15 August 2018
Following the resignation of Dr Andrew Cheng, chief medical officer of US biotech major Gilead Sciences, the company has announced two promotions. 15 August 2018
Paragon Biosciences’ portfolio company Emalex Biosciences has acquired fellow USA-based Psyadon Pharmaceuticals, a biopharmaceutical company dedicated to the development of new treatments for rare and orphan neurological conditions. 14 August 2018
Vienna, Austria-based biotech firm Haplogen has entered into a multi-year drug discovery and development collaboration with German pharma major Bayer to identify new therapeutics with applications in pulmonary diseases such as chronic obstructive pulmonary disease (COPD). 14 August 2018
Shares in rare disease specialist Amicus Therapeutics unsurprisingly closed up on Friday following the approval of its Fabry disease drug Galafold (migalastat), but it was a different story on Monday. 14 August 2018
An established allergy drug has now been granted Breakthrough Therapy designation (BTD), aimed at expediting the development and approval process, by the US Food and Drug Administration in the food allergy space. 14 August 2018
News of challenges to US biotech giant Gilead Sciences’ intellectual property in overseas markets is commonplace, with the company conceding patents relating to its hepatitis C drugs in China this week. 14 August 2018
The USA-based non-profit campaigner on patents, I-MAK, has claimed a significant victory in its bid to bring hepatitis C treatments that were previously protected by patents to the world’s largest patient population. 14 August 2018
Namir Hassan has been named chief scientific officer of Zelluna Immunotherapy, a privately-held Norwegian biotech specializing in T-cell receptor (TCR) immunotherapies. 13 August 2018
Due to ongoing labeling discussions, the US Food and Drug Administration has issued a complete response letter (CRL) regarding the supplemental Biologics License Application (sBLA) for Eylea (aflibercept) Injection in patients with wet age-related macular degeneration (wet AMD). 13 August 2018
Accelerator Life Science Partners and the University of Texas MD Anderson Cancer Center have announced the launch of Magnolia Neurosciences, a drug discovery and development company focused on creating a novel class of neurological therapies. 13 August 2018
There has been a steady drumbeat of failure in the race to develop a third-generation EGFR inhibitor to compete with Tagrisso (osimertinib) from AstraZeneca in an around $5 billion market. 13 August 2018
The US Food and Drug Administration has approved Onpattro (patisiran) lipid complex injection, a first-of-its-kind RNA interference (RNAi) therapeutic, for the treatment of the polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults. 11 August 2018
The US Food and Drug Administration on Friday granted accelerated approval for Galafold (migalastat), the first oral medication for the treatment of adults with Fabry disease. 11 August 2018
An investigation by The Times of London has led to the UK's National Health Service (NHS) scrapping its restrictions on the use of Imbruvica (ibrutinib). 10 August 2018